Document:

Management Rights Agreement

 Exhibit 10.10 
 Execution Version 
 MANAGEMENT RIGHTS AGREEMENT 

Ladies and Gentlemen: 
 This
letter agreement (this “Letter Agreement”) is being executed and delivered to confirm agreements with respect to the investment by TPG Biotechnology Partners II, L.P. (the “Partnership”) in Quintiles Transnational
Corp. (the “Company”) and certain management rights that the Company conferred upon the Partnership in connection with such investment so that investment may qualify as a “venture capital investment” within the meaning of
the Department of Labor regulation Section 2510.3-101, as modified by Section 3(42) of ERISA (the “Plan Asset Regulation”). 
  

	1.	Management Rights 

(a) The Partnership shall have the following rights and entitlements: 

(i) The Partnership shall be entitled, from time to time and at the Partnership’s expense, to make proposals, recommendations and
suggestions to the board of directors of the Company (the “Board of Directors”) at a scheduled meeting of the Board of Directors and relating to the business and affairs of the Company and any subsidiary of the Company upon the
request of the Partnership or the Company and subject to reasonable advance notice. The Board of Directors shall consider in good faith all proposals, recommendations and suggestions made by the Partnership pursuant to the foregoing sentence;
provided, however, that nothing in this clause (a)(i) shall obligate, or be deemed to obligate, the Board of Directors to adopt or implement any proposal, recommendation or suggestion made by or on behalf of the Partnership.

 (ii) The Company shall permit the Partnership, at reasonable times and at the Partnership’s expense, to discuss the
business and affairs of the Company and its subsidiaries with the management of the Company; provided, in all cases, that: 
 (A) The Partnership shall give at least two (2) business days prior written notice to an officer of the Company identifying all person(s) with whom the Partnership wishes to have discussions and
specifying in reasonable detail the nature of the information sought from such person(s) and the purpose(s) for which the Partnership wishes to obtain such information; 

(B) During any discussion or at any meeting between the Partnership and such person(s), the Partnership shall not inquire
into matters not specified in such notice; and 
 (C) The Company shall have the right to have representatives,
in addition to the person(s) being made available, present during any such discussion or meeting. 

 (iii) The Company shall permit the Partnership, at reasonable times and at the
Partnership’s expense, to examine such books, records, documents and other written information in the possession of the Company relating to the affairs of the Company and its subsidiaries as the Partnership may reasonably request;
provided, in all cases, that the Partnership shall give at least two (2) business days prior written notice to the Company describing in reasonable detail the books, records, documents and other written information which the Partnership
wishes to examine and specifying the purpose(s) for which the Partnership wishes to make such examination. 
 (iv) The Company
shall permit the Partnership, at reasonable times and at the Partnership’s expense, to visit and inspect the properties of the Company and its subsidiaries; provided, in all cases, that the Partnership shall give at least two
(2) business days prior written notice to the Company describing in reasonable detail the properties which the Partnership wishes to inspect and specifying the purpose(s) for which the Partnership wishes to make such inspection. 

(b) The Partnership hereby agrees that it will not request or otherwise seek to obtain any information pursuant to the foregoing
provisions, and will not use (or permit to be used) any information obtained pursuant to the foregoing provisions, except for lawful purposes relating solely to the Partnership’s interest as investor. Without limitation of the foregoing, the
Partnership hereby agrees that it will not use (or permit to be used) any information obtained in connection with the foregoing provisions in any manner that is unlawful or is adverse or detrimental to the Company. As a condition to exercising their
examination and inspection rights under Sections 1(a)(iii) and 1(a)(iv) above, the Partnership shall be required to comply with the Company’s normal requirements regarding health, safety, security and operational matters. 

(c) The Partnership agrees that it will keep confidential and not disclose any confidential, proprietary or secret information which the
Partnership may obtain from the Company, unless such information is or becomes known to the Partnership from a source other than the Company or is or becomes publicly known, or unless the Company gives its written consent to the Partnership’s
release of such information, except that no such written consent shall be required (and the Partnership shall be free to release such information to such recipient) if such information is to be provided to the Partnership’s counsel or
accountant, or to an officer, director or partner of the Partnership, provided that the Partnership shall inform the recipient of the confidential nature of such information, and shall instruct the recipient to treat the information as confidential.

  
 2 

	2.	Miscellaneous 

 (a)
Except as provided in Section 2(b) below, the rights conferred under this Letter Agreement shall automatically terminate on the date the Partnership ceases to maintain, directly or indirectly, any investment in the Company. 

(b) In the event that the Partnership transfers all or any portion of its investment to an affiliated entity that is (i) a Permitted
Transferee (as defined in the Shareholders Agreement, dated January 22, 2008, among the Company and the investors named therein, including the Partnership) and (ii) intended to qualify as a venture capital operating company under the Plan
Asset Regulation, such transferee shall be afforded the same rights with respect to the Company afforded to the Partnership hereunder and shall be treated, for such purposes, as a third party beneficiary hereunder. 

(c) Anything herein or elsewhere to the contrary notwithstanding, the rights and obligations of the Company and the Partnership under
this agreement are subject to all applicable laws. Accordingly, the Partnership shall not be entitled to exercise or enforce any right purported to be conferred upon it by the provisions of this Letter Agreement and the Company shall not be required
to perform any of its covenants contained in this Letter Agreement, in each case, if and to the extent the exercise or enforcement of such right or the performance of such obligation, as the case may be, would violate or constitute or result in a
breach of (i) any law, statute (including, without limitation, antitrust laws), ordinance, rule or regulation or any injunction, restraining order or other court order or decree applicable to the Company or any of its directors, officers or
employees (or their equivalents) or any pronouncement having the effect of law or (ii) any contract, lease, commitment, agreement or other instrument binding upon the Company. 

(d) This Letter Agreement and its validity, construction and performance shall be governed in all respects by, and construed in
accordance with, the laws of the State of New York, without regard to principles of conflicts of law. This Letter Agreement may be executed in counterparts, each of which when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same instrument. 
 (e) This Letter Agreement represents the entire agreement of the
parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, between the parties with respect to the subject matter. 

(f) If, pursuant to a subsequent change in the law or the issuance of new interpretive guidance by the U.S. Department of Labor, the
rights granted in this letter are required to be altered in order to preserve the qualification of the Partnership as a “venture capital operating company” or otherwise to ensure that the assets of the Partnership are not considered
“plan assets” for purposes of ERISA, the Company and the Partnership agree to cooperate to amend this letter to effect any such alteration, provided that no such alteration would have a material adverse effect on the business operations or
prospects of the Company or its subsidiaries. 

  
 3 

 To indicate your agreement of the foregoing, please sign and return the duplicate enclosed
copy of this Letter Agreement to the undersigned. 
  

									
	Very truly yours,
		
		 	TPG Biotechnology Partners II, L.P.
			
		 	By:	 	TPG Biotechnology GenPar II, L.P., its General Partner
			
		 	By:	 	TPG Biotech Advisors II, L.L.C. its General Partner
				
		 		 	By:	 	 /s/ Clive D. Bode

		 		 		 	Name:	 	Clive Bode
		 		 		 	Title:	 	Vice President

  

							
		 	ACKNOWLEDGED AND AGREED TO AS OF THE DATE FIRST ABOVE WRITTEN:
		
		 	Quintiles Transnational Corp.
			
		 	By:	 	 /s/ Ron Wooten

		 		 	Name:	 	RON WOOTEN
		 		 	Title:	 	EVP

  
 4Management Rights Agreement

 Exhibit 10.11 
 MANAGEMENT RIGHTS AGREEMENT 
 Ladies and Gentlemen: 

This letter agreement (this “Letter Agreement”) is being executed and delivered to confirm agreements with respect to
the investment by 3i US Growth Healthcare Fund 2008 L.P. (the “Partnership”) in Quintiles Transnational Corp. (the “Company”) and certain management rights that the Company conferred upon the Partnership in
connection with such investment so that investment may qualify as a “venture capital investment” within the meaning of the Department of Labor regulation Section 2510.3-101, as modified by Section 3(42) of ERISA (the
“Plan Asset Regulation”). 
  

	1.	Management Rights 

(a) The Partnership shall have the following rights and entitlements: 

(i) The Partnership shall be entitled, from time to time and at the Partnership’s expense, to make proposals, recommendations and
suggestions to the board of directors of the Company (the “Board of Directors”) at a scheduled meeting of the Board of Directors and relating to the business and affairs of the Company and any subsidiary of the Company upon the
request of the Partnership or the Company and subject to reasonable advance notice. The Board of Directors shall consider in good faith all proposals, recommendations and suggestions made by the Partnership pursuant to the foregoing sentence;
provided, however, that nothing in this clause (a)(i) shall obligate, or be deemed to obligate, the Board of Directors to adopt or implement any proposal, recommendation or suggestion made by or on behalf of the Partnership.

 (ii) The Company shall permit the Partnership, at reasonable times and at the Partnership’s expense, to discuss the
business and affairs of the Company and its subsidiaries with the management of the Company; provided, in all cases, that: 
 (A) The Partnership shall give at least two (2) business days prior written notice to an officer of the Company identifying all person(s) with whom the Partnership wishes to have discussions and
specifying in reasonable detail the nature of the information sought from such person(s) and the purpose(s) for which the Partnership wishes to obtain such information; 

(B) During any discussion or at any meeting between the Partnership and such person(s), the Partnership shall not inquire
into matters not specified in such notice; and 
 (C) The Company shall have the right to have representatives,
in addition to the person(s) being made available, present during any such discussion or meeting. 

 (iii) The Company shall permit the Partnership, at reasonable times and at the
Partnership’s expense, to examine such books, records, documents and other written information in the possession of the Company relating to the affairs of the Company and its subsidiaries as the Partnership may reasonably request;
provided, in all cases, that the Partnership shall give at least two (2) business days prior written notice to the Company describing in reasonable detail the books, records, documents and other written information which the Partnership
wishes to examine and specifying the purpose(s) for which the Partnership wishes to make such examination. 
 (iv) The Company
shall permit the Partnership, at reasonable times and at the Partnership’s expense, to visit and inspect the properties of the Company and its subsidiaries; provided, in all cases, that the Partnership shall give at least two
(2) business days prior written notice to the Company describing in reasonable detail the properties which the Partnership wishes to inspect and specifying the purpose(s) for which the Partnership wishes to make such inspection. 

(v) At any time when the Partnership does not have a representative on the Board of Directors, the Partnership, at the Partnership’s
expense, shall have the right to have a representative present at all meetings of the Board of Directors, except that the representative may be excluded from access to any meeting or portion thereof if the Board of Directors determines in good
faith, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege. 
 (b) The
Partnership hereby agrees that it will not request or otherwise seek to obtain any information pursuant to the foregoing provisions, and will not use (or permit to be used) any information obtained pursuant to the foregoing provisions, except for
lawful purposes relating solely to the Partnership’s interest as investor. Without limitation of the foregoing, the Partnership hereby agrees that it will not use (or permit to be used) any information obtained in connection with the foregoing
provisions in any manner that is unlawful or is adverse or detrimental to the Company. As a condition to exercising their examination and inspection rights under Sections 1(a)(iii) and 1(a)(iv) above, the Partnership shall be required to comply with
the Company’s normal requirements regarding health, safety, security and operational matters. 
 (c) The Partnership agrees
that it will keep confidential and not disclose any confidential, proprietary or secret information which the Partnership may obtain from the Company, unless such information is or becomes known to the Partnership from a source other than the
Company or is or becomes publicly known, or unless the Company gives its written consent to the Partnership’s release of such information, except that no such written consent shall be required (and the Partnership shall be free to release such
information to such recipient) if such information is to be provided to the Partnership’s counsel or accountant, or to an officer, director or partner of the Partnership, provided that the Partnership shall inform the recipient of the
confidential nature of such information, and shall instruct the recipient to treat the information as confidential. 

  
 2 

	2.	Miscellaneous 

 (a)
Except as provided in Section 2(b) below, the rights conferred under this Letter Agreement shall automatically terminate on the date the Partnership ceases to maintain, directly or indirectly, any investment in the Company. 

(b) In the event that the Partnership transfers all or any portion of its investment to an affiliated entity that is (i) a Permitted
Transferee (as defined in the Shareholders Agreement, dated January 22, 2008, among the Company and the investors named therein, including the Partnership) and (ii) intended to qualify as a venture capital operating company under the Plan
Asset Regulation, such transferee shall be afforded the same rights with respect to the Company afforded to the Partnership hereunder and shall be treated, for such purposes, as a third party beneficiary hereunder. 

(c) Anything herein or elsewhere to the contrary notwithstanding, the rights and obligations of the Company and the Partnership under
this agreement are subject to all applicable laws. Accordingly, the Partnership shall not be entitled to exercise or enforce any right purported to be conferred upon it by the provisions of this Letter Agreement and the Company shall not be required
to perform any of its covenants contained in this Letter Agreement, in each case, if and to the extent the exercise or enforcement of such right or the performance of such obligation, as the case may be, would violate or constitute or result in a
breach of (i) any law, statute (including, without limitation, antitrust laws), ordinance, rule or regulation or any injunction, restraining order or other court order or decree applicable to the Company or any of its directors, officers or
employees (or their equivalents) or any pronouncement having the effect of law or (ii) any contract, lease, commitment, agreement or other instrument binding upon the Company. 

(d) This Letter Agreement and its validity, construction and performance shall be governed in all respects by, and construed in
accordance with, the laws of the State of New York, without regard to principles of conflicts of law. This Letter Agreement may be executed in counterparts, each of which when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same instrument. 
 (e) This Letter Agreement represents the entire agreement of the
parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, between the parties with respect to the subject matter. 

(f) If, pursuant to a subsequent change in the law or the issuance of new interpretive guidance by the U.S. Department of Labor, the
rights granted in this letter are required to be altered in order to preserve the qualification of the Partnership as a “venture capital operating company” or otherwise to ensure that the assets of the Partnership are not considered
“plan assets” for purposes of ERISA, the Company and the Partnership agree to cooperate to amend this letter to effect any such alteration, provided that no such alteration would have a material adverse effect on the business operations or
prospects of the Company or its subsidiaries. 

  
 3 

 To indicate your agreement of the foregoing, please sign and return the duplicate enclosed
copy of this Letter Agreement to the undersigned. 
  

							
	Very truly yours,
	
	3i US Growth Healthcare Fund 2008 L.P.
		
	By:	 	3i U.S. Growth Corporation, its General Partner
			
		 	By:	 	 /s/ Robin Marshall

		 		 	Name:	 	Robin Marshall
		 		 	Title:	 	Senior Vice President

  

					
	ACKNOWLEDGED AND AGREED TO AS OF THE DATE FIRST ABOVE WRITTEN:
	
	Quintiles Transnational Corp.
		
	By:	 	 /s/ Ron Wooten

		 	Name:	 	Ron Wooten
		 	Title:	 	EVP

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]